An Orally Bioavailable, Functionally Selective Inverse Agonist at the Benzodiazepine Site of GABAA α5 Receptors with Cognition Enhancing Properties
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
(3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)pyrazolo[1,5-d][1,2,4]triazine (13) has been identified as a functionally selective, inverse agonist at the benzodiazepine site of GABA(A) alpha5 receptors. 13 is orally bioavailable, readily penetrates the CNS, and enhances performance in animal models of cognition. It does not exhibit the convulsant, proconvulsant, or anxiogenic activity associated with nonselective GABA(A) inverse agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Which GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Self-citationCollinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628
Self-citation
Cited by
GABAA receptors: Subtypes provide diversity of function and pharmacology
Olsen, R. W., & Sieghart, W. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.045 · Cited by 982
Extrasynaptic GABAA Receptors: Their Function in the CNS and Implications for Disease
Brickley, S. G., & Mody, I. (2012) · Neuron · doi:10.1016/j.neuron.2011.12.012 · Cited by 676
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: A narrative review
Fineberg, N. A., Potenza, M. N., Chamberlain, S. R., Berlin, H. A., Menzies, L., Bechara, A., Sahakian, B. J., Robbins, T. W., Bullmore, E. T., & Hollander, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.185 · Cited by 654
“…also of the doubly dissociable findings of Carli et alFthat infusions of the 5-HT1A agonist into the infralimbic region reduced perseverative behavior (on the 5-CSRTT) without influencing impulsive responding, with a 5-HT2A receptor antagonist having the opposite effect (Chambers et al, 2004).”
ResultThe GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
GABAA receptor diversity and pharmacology
Möhler, H. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0284-3 · Cited by 363
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Structure, Pharmacology, and Function of GABAA Receptor Subtypes
Sieghart, W. (2006) · Advances in Pharmacology · doi:10.1016/s1054-3589(06)54010-4 · Cited by 317
Samuelsson, A.-M., Jennische, E., Hansson, H.-A., & Holmäng, A. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00268.2005 · Cited by 285
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 225
“agonists at a5-containing GABAA receptors have been demonstrated to enhance performance in animal models of cognition, apparently without lowering the seizure threshold as seen with nonselective GABAA inverse agonists.(274,275) In addition, a5 subunit knockout mice demonstrate increased hippocampal activity due to the…”
BackgroundPrepulse inhibition and genetic mouse models of schizophrenia
Powell, S. B., Zhou, X., & Geyer, M. A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.021 · Cited by 218
“GABAA receptor inverse agonists have recently been shown to be cognitive enhancers in the delayed matching to position version of the water maze [34,44,186].”
BackgroundRegulating anxiety with extrasynaptic inhibition
Botta, P., Demmou, L., Kasugai, Y., Markovic, M., Xu, C., Fadok, J. P., Lu, T., Poe, M. M., Xu, L., Cook, J. M., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4102 · Cited by 192
Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188
Self-citationSynaptic and nonsynaptic localization of GABAAreceptors containing the α5 subunit in the rat brain
Serwanski, D. R., Miralles, C. P., Christie, S. B., Mehta, A. K., Li, X., & De Blas, A. L. (2006) · Journal of Comparative Neurology · doi:10.1002/cne.21115 · Cited by 164
“© 2006 WILEY-LISS, INC. compounds as cognition enhancers for clinical use (Chambers et al., 2004; Sternfeld et al., 2004).”
BackgroundAli, A. B., & Thomson, A. M. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm160 · Cited by 129
GABAA receptor subtypes underlying general anesthesia
Bonin, R. P., & Orser, B. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.011 · Cited by 85
Role of GABAA receptors in cognition
Möhler, H. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371328 · Cited by 79
Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists
Martínez-Cué, C., Delatour, B., & Potier, M.-C. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.12.008 · Cited by 58
Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
Potier, M.-C., Braudeau, J., Dauphinot, L., & Delatour, B. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660185 · Cited by 34
“triazolophtalazines α5 inverse agonist (α5ΙΑ) from Merck laboratories [42-46] and more recently the”
BackgroundMethodGhafari, M., Falsafi, S. K., Szodorai, E., Kim, E.-J., Li, L., Höger, H., Berger, J., Fuchs, K., Sieghart, W., & Lubec, G. (2017) · Brain Structure and Function · doi:10.1007/s00429-016-1233-x · Cited by 19
“Finally, a growing body of evidence highlights cognition enhancing properties of selective inverse agonists (negative allosteric modulators) for a5GABA A Rs in a water maze task (Collinson et al. 2006; Chambers et al. 2004; Dawson et al. 2006).”
BackgroundPharmacological Properties of DOV 315,090, an ocinaplon metabolite
Berezhnoy, D., Gravielle, M. C., Downing, S., Kostakis, E., Basile, A. S., Skolnick, P., Gibbs, T. T., & Farb, D. H. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-11 · Cited by 18
Metadata
- Authors
- Chambers, M. S., Atack, J. R., Carling, R. W., Collinson, N., Cook, S. M., Dawson, G. R., Ferris, P., Hobbs, S. C., O'Connor, D., Marshall, G., Rycroft, W., & MacLeod, A. M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-10-16
- Volume
- 47
- Issue
- 24
- Pages
- 5829-5832
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2042887680
- Cited by
- 109
- References
- 5
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.